Medicare Advantage与老年透析患者活体肾移植可及性的关联
本研究基于美国肾脏数据系统2015-2021年启动透析的65-80岁成人(N=284,166),评估Medicare Advantage与传统Medicare相比对肾移植等待名单登记及移植可及性的影响。结果显示Medicare Advantage与较低的等待名单登记率相关(sHR 0.87),等待登记后与较低的活体供肾移植率相关(sHR 0.85),但与 deceased donor 移植或任何移植无显著关联。
要点
- Medicare Advantage与老年透析患者等待名单登记率较低相关(sHR 0.87)。
- 等待登记后,Medicare Advantage与活体供肾移植率较低相关(sHR 0.85)。
- Medicare Advantage与 deceased donor 移植或任何移植无显著关联。
核心结论
- 在启动透析的老年肾衰竭患者中,Medicare Advantage与较低的等待名单登记率及等待登记后较低的活体供肾移植率相关,但与 deceased donor 移植或任何移植无显著关联。
研究设计与样本
- 基于美国肾脏数据系统的回顾性队列研究,纳入2015-2021年启动透析的65-80岁成人(N=284,166;分析样本N=279,229),随访至2024年3月15日。
- 使用Fine-Gray竞争风险模型估计等待名单登记(死亡为竞争事件)及等待登记后移植(死亡和退出等待为竞争事件)的亚分布风险比(sHR)。
主要发现
- 在279,229例调整模型中,15,664例(6%)进入等待名单。
- Medicare Advantage与传统Medicare相比,等待名单登记的可能性较低(sHR 0.87;95% CI 0.84-0.90)。
- 等待登记患者中,Medicare Advantage与任何肾移植发生率无关(sHR 0.99;95% CI 0.94-1.03),与 deceased donor 肾移植无关(sHR 1.04;95% CI 0.99-1.10),但与活体供肾移植发生率较低相关(sHR 0.85;95% CI 0.77-0.94)。
临床怎么用
- 对于老年透析患者,Medicare Advantage保险类型可能影响肾移植等待登记及活体供肾移植的可及性,临床评估时应关注保险相关障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Medicare Advantage was associated with lower kidney transplant waitlisting among older adults initiating dialysis. After waitlisting, Medicare Advantage was associated with lower living donor kidney transplantation but not deceased donor transplantation. Findings suggest payer-related barriers may differ across transplant pathway steps and living donor processes. BACKGROUND: Medicare Advantage enrollment is rising among older adults with kidney failure. Compared with traditional Medicare, the contracted provider networks and utilization management of Medicare Advantage may introduce friction in transplant evaluation and living donor coordination, potentially restricting access for vulnerable beneficiaries. We examined whether Medicare Advantage is associated with access to living donor kidney transplantation and whether associations vary by rurality, age, or county-level social vulnerability. METHODS: Using the United States Renal Data System, we identified adults aged 65-80 years initiating dialysis in 2015-2021 with follow-up through March 15, 2024 ( N =284,166; analytic N =279,229 with complete covariate data). Payer was classified at day 90 after dialysis initiation for waitlisting and overall incident-cohort models and at waitlisting for postwaitlisting transplant models. Fine-Gray competing risks models estimated subdistribution hazard ratios (sHRs) for time to waitlisting (death as the competing event) and, among waitlisted patients, time to any transplantation (death and delisting as competing events) and to deceased donor kidney transplantation or living donor kidney transplantation (death, delisting, and receipt of the alternate donor type as competing events). We adjusted for demographics, dual eligibility, clinical factors, rurality, and county-level Social Vulnerability Index quartiles. RESULTS: Forty-two percent were enrolled in Medicare Advantage. Among 279,229 patients in adjusted models, 15,664 (6%) were waitlisted. Medicare Advantage was associated with lower likelihood of waitlisting versus traditional Medicare (sHR, 0.87; 95% confidence interval [CI], 0.84 to 0.90). Among waitlisted patients, Medicare Advantage was not associated with the incidence of any kidney transplantation (sHR, 0.99; 95% CI, 0.94 to 1.03) or deceased donor kidney transplantation (sHR, 1.04; 95% CI, 0.99 to 1.10) but was associated with a lower incidence of living donor kidney transplantation (sHR, 0.85; 95% CI, 0.77 to 0.94). CONCLUSIONS: Among older adults with kidney failure initiating dialysis, Medicare Advantage was associated with lower waitlisting and lower living donor kidney transplantation after waitlisting but was not associated with deceased donor kidney transplantation or any kidney transplantation after waitlisting.
引用
- Adler JT, Kuk AE, Drewry KM, et al. Medicare Advantage and Access to Living Donor Kidney Transplantation among Older Patients Receiving Dialysis. J Am Soc Nephrol. 2026. PMID: 42555210. doi:10.1681/ASN.0000001209
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。